Thematic report · November 1, 2026
The Promising Sector: Biotech & Peptides
Prices as of the October 30, 2026 close. Written in Arabic; this page is an English summary of the key findings.
Why biotech now
Faster approvals. The FDA's National Priority Voucher program (CNPV), launched in 2025 under the Trump administration, cuts priority drug reviews from about a year to one or two months. Eli Lilly's orforglipron (Foundayo) pill won one of the fastest approvals of a new drug since 2002, and daraxonrasib for pancreatic cancer was approved about a month after filing.
Treatments for diseases that had none. RAS, long called “undruggable”, now has an approved drug in pancreatic cancer, one of the deadliest cancers. GLP-1 drugs have become among the best-selling medicines in the world.
Why it matters to investors. Less time between results and revenue means less cash burned and faster value for shareholders.
Case study: Revolution Medicines (RVMD)
Thahlan flagged RVMD in May 2026 at about $144. On August 26 the FDA approved daraxonrasib for pancreatic cancer, about a month after the application was complete and roughly six and a half months ahead of the normal timeline. The stock closed October 30 at $191.31 (market value about $41B): +33% since our note, after peaking at +53% ($221) following the approval.
- Oct 2025: the drug received a national priority voucher.
- Apr 13, 2026: phase 3 results doubled survival; the stock jumped from $96 to $136.
- May 30: expanded-access program for patients ahead of approval.
- Aug 26: FDA approval.
Solving one cancer opens the door to others
RAS acts like a growth switch stuck in the “on” position. RAS mutations appear in about 90% of pancreatic cancers, 40–45% of colorectal cancers and about 30% of non-small-cell lung cancers, and are linked to roughly 30% of cancer deaths. Because the drug targets the mutation rather than the organ, success in the pancreas is now being tested in lung (RASolve 301) and earlier-stage pancreatic cancer.
On the radar: Veradermics (MANE)
VDPHL01 is an extended-release oral minoxidil for hereditary hair loss, not yet approved. In trials, hair growth was 5.5x placebo after six months, and 85% of men on the twice-daily dose saw clear improvement, with no drug-related serious side effects across more than 1,000 participants. The stock closed October 30 at $139.69 (about $5.8B), up more than 4x from its 52-week low of $32.
Watch for: 12-month safety data later in 2026, a women's trial (556 participants) in the first half of 2027, and an FDA filing date that has not yet been set.
Peptides and quality of life
Peptides are short chains of amino acids, the same family as insulin and GLP-1. Evidence is very strong in obesity and type 2 diabetes, strong in osteoporosis, heart and sleep apnea, and cancer imaging and therapy, and weak for hair loss and injury-healing peptides such as BPC-157 and TB-500.
The next wave: Lilly's retatrutide (28.3% average weight loss over 80 weeks), and GLP-1 pills now on the market. A caution: on October 28, 2026 the US health department allowed compounding pharmacies to prepare six peptides by prescription, including BPC-157 and TB-500. That is not FDA approval, and products sold “for research use only” carry no guarantee of purity or dose.
Risks and the Thahlan view
Risks: a single failed trial can cut a small company's stock by 70–90% in a day; drug-price pressure and government negotiation; generic competition when patents expire; side effects; and volatility, as RVMD itself fell about 20% from its peak after approval.
Our view: biotech is among the most promising sectors for the coming years, but the large returns come from careful company selection, not from buying the whole sector. We favor companies with strong phase 3 data and enough cash to reach revenue.
The full 13-page report also covers peptide economics, the off-label and grey market, the key companies and US policy, and the official government documents behind the analysis.
Download full report (PDF, Arabic)
This is a general report for information and education only. It is not a recommendation to buy or sell any security. Past performance does not guarantee future results. Consult your doctor before using any drug or peptide.